Τίτλος:
Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Our aims were to identify factors associated with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) in patients with hematological malignancies and evaluate the outcome of the affected patients. Consecutive patients with hematological malignancies who developed PA BSI were identified. Subsequently, two case–control studies were performed to evaluate the risk factors (i) for PA BSI and (ii) for carbapenem resistant (CR) PA BSI. Patients' outcome was evaluated at 28 days after the onset of bacteraemia. A total of 64 patients with PA BSI (45 caused by CS and 19 by CR organisms) and 128 without PA BSI were enrolled. Patients with rapidly fatal disease, steroid use, neutropenia or prior surgery were more likely to develop PA BSI, whereas patients with previous hospitalization and prior use of fluoroquinolones were more likely to develop CR PA BSI. The 28-day mortality rate was 35.9%. Severity of sepsis was the only independent predictor of adverse outcome. © 2017 Elsevier Inc.
Συγγραφείς:
Tofas, P.
Samarkos, M.
Piperaki, E.-T.
Kosmidis, C.
Triantafyllopoulou, I.-D.
Kotsopoulou, M.
Pantazatou, A.
Perlorentzou, S.
Poulli, A.
Vagia, M.
Daikos, G.L.
Περιοδικό:
Diagnostic Microbiology and Infectious Disease
Εκδότης:
HANLEY & BELFUS-ELSEVIER INC
Λέξεις-κλειδιά:
amikacin; aminoglycoside antibiotic agent; carbapenem; ciprofloxacin; doripenem; gentamicin; imipenem; levofloxacin; meropenem; moxifloxacin; quinoline derived antiinfective agent; steroid; antiinfective agent; carbapenem derivative; quinolone derivative, adult; adverse outcome; antibiotic resistance; Article; bacterial growth; bloodstream infection; case control study; controlled study; disease association; disease severity; drug megadose; drug use; fatality; female; Gram negative sepsis; hematologic malignancy; hospitalization; human; infection risk; major clinical study; male; middle aged; mortality rate; neutropenia; nonhuman; outcome assessment; patient history of surgery; prediction; priority journal; Pseudomonas aeruginosa; Pseudomonas infection; risk assessment; risk factor; treatment outcome; bacteremia; drug effects; hematologic disease; microbiology; Pseudomonas infection; risk factor; treatment outcome, Anti-Bacterial Agents; Bacteremia; Carbapenems; Case-Control Studies; Drug Resistance, Bacterial; Female; Fluoroquinolones; Hematologic Neoplasms; Hospitalization; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Treatment Outcome
DOI:
10.1016/j.diagmicrobio.2017.05.003
